Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics, Inc. (ARQT) is a leader in developing innovative topical therapies for immune-mediated skin conditions. This page provides investors and medical professionals with essential updates on FDA approvals, clinical trial progress, and strategic initiatives shaping the future of dermatological care.
Access authoritative information about ARQT's non-steroidal treatments for conditions including atopic dermatitis and plaque psoriasis. Our curated news collection features regulatory milestones, research developments, and market analyses to help stakeholders track the company's progress in addressing unmet medical needs.
Key updates include new product launches, clinical trial results, partnership announcements, and scientific presentations. All content is verified through primary sources to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Arcutis' latest advancements in immuno-dermatology. Check regularly for updates on pipeline developments and peer-reviewed research findings that demonstrate the company's commitment to transforming skin disease treatment.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) presented new data on roflumilast foam for psoriasis treatment at the AAD Virtual Meeting on April 23-25, 2021. The Phase 2b study showed that roflumilast foam was well-tolerated and significantly improved scalp and body psoriasis as early as two weeks after treatment initiation. The foam achieved a primary endpoint success of 59.1% for scalp psoriasis by week eight, compared to 11.4% for the vehicle. Additional findings supported the foam's efficacy for seborrheic dermatitis and roflumilast cream for chronic plaque psoriasis, highlighting its potential as a new treatment option.
Arcutis Biotherapeutics (Nasdaq: ARQT) announces new data presentations on its topical roflumilast cream and foam for treating chronic plaque psoriasis, scalp psoriasis, and seborrheic dermatitis, during the American Academy of Dermatology Virtual Meeting Experience from April 23-25, 2021. Key highlights include results from a Phase 2b study of roflumilast foam and various sub-analyses of the cream. Chief Medical Officer Patrick Burnett emphasized the unmet needs in treatment options for these conditions. If approved by the FDA, these therapies could significantly improve patient care.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the initiation of a pivotal Phase 3 trial for its topical roflumilast cream (ARQ-151) targeting mild-to-moderate atopic dermatitis in children aged 2 to 5. With approximately 19 million affected in the U.S., the trial aims to assess safety, efficacy, and tolerability. Enrolling around 650 subjects, the study will measure primary and secondary endpoints, with topline data expected in the second half of 2022. If successful, roflumilast cream may provide a new treatment option in a field with limited alternatives.
Arcutis Biotherapeutics (Nasdaq: ARQT) announces executive leadership changes as it prepares for the commercialization of its pipeline products. Scott Burrows will succeed John Smither as CFO effective April 1, 2021, after Smither's retirement. Burrows has 20 years of finance experience in the biopharmaceutical industry. Corey Padovano has been appointed Vice President of Sales, bringing 20 years of leadership experience. Sean Brugger joins as Executive Director of Field Medical Affairs, focused on scientific communications. These changes aim to enhance Arcutis' growth as it approaches its first New Drug Application.
Arcutis Biotherapeutics announced the enrollment of the first patient in a Phase 2a trial for ARQ-252, a selective JAK1 inhibitor, as a potential treatment for vitiligo, affecting approximately 1.3 million U.S. patients. This double-blind, vehicle-controlled study will evaluate ARQ-252 in combination with narrowband UVB therapy in about 500 subjects. The primary endpoint is ≥ 75% improvement in facial vitiligo area at week 24. Results are expected in the second half of 2023, aiming to provide better efficacy for patients dissatisfied with current off-label treatments.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced new data for roflumilast cream, focusing on long-term safety and efficacy outcomes in adults with chronic plaque psoriasis. The presentations at the Innovations in Dermatology virtual conference highlighted results from a Phase 2 long-term safety study and the Phase 3 studies' positive topline data. The cream aims to address limitations of existing treatments by offering a favorable profile for chronic use. The company plans to submit a New Drug Application soon, potentially revolutionizing treatment standards for various dermatological conditions.
Arcutis Biotherapeutics (Nasdaq: ARQT), a late-stage biopharmaceutical company, will present at the Cowen 41st Annual Health Care Conference scheduled for March 1-4, 2021. The presentation will occur on March 1 at 12:20 p.m. PT / 3:20 p.m. ET and will focus on their advancements in immuno-dermatology. Interested parties can access the presentation via webcast on the company’s website, with an archived replay available for 30 days post-conference. Arcutis aims to address unmet needs in dermatological treatments, highlighting their lead candidate for various skin conditions.
On February 18, 2021, Arcutis Biotherapeutics (Nasdaq: ARQT) announced that Courtney Barton joins as Chief Compliance Officer and Chief of Staff. Barton brings over 17 years of experience in corporate and healthcare compliance, having previously served as Vice President at Cipla Therapeutics. Her role will enhance Arcutis' compliance and data privacy efforts, aligning with the company's goal to establish itself as a leading innovation-driven medical dermatology firm. This strategic appointment is expected to support Arcutis' growth and commitment to integrity in operations.
Arcutis Biotherapeutics (NASDAQ: ARQT) announced positive Phase 3 results for its topical roflumilast cream targeting plaque psoriasis, with a New Drug Application (NDA) submission expected in H2 2021. The company plans to advance three additional programs into pivotal Phase 3 trials in 2021. Financially, Arcutis holds over $470 million in cash, providing a runway into 2023. R&D expenses rose significantly due to the initiation of multiple clinical trials, with a net loss of $135.7 million for 2020. The company aims to address unmet medical needs affecting over 20 million patients, with potential revenue opportunities of $3 to $8 billion.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the completion of a public offering, raising approximately $221.4 million by selling a total of 6,325,000 shares of common stock at $35 per share. The offering included the exercise of an overallotment option for an additional 825,000 shares. The funds are intended to support the development of Arcutis' pipeline, which focuses on immuno-dermatology treatments. Major underwriters for the offering included Morgan Stanley, Cowen, and Guggenheim Securities.
FAQ
What is the current stock price of Arcutis Biotherapeutics (ARQT)?
What is the market cap of Arcutis Biotherapeutics (ARQT)?
